^
Association details:
| Biomarker: | CHEK2 mutation + ATM mutation + BRCA2 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) + Bavencio (avelumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1335P - Anti-tumour efficacy of cetuximab plus avelumab in NSCLC through induction of ADCC: Final data from CAVE-lung trial
Published date:
09/14/2020
Excerpt:
We explored efficacy and safety of C plus A in a single arm proof of concept study in relapsed NSCLC….Among R pts, we found one STK11/TP53 co-mut, and CHK2/ATM/BRCA2 co-mut and MDM2 mut in those 2 pts previously treated with anti-PD1, respectively.
